{"entity":{"id":"nct05668858","kind":"trial","name":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","aka":[],"tldr":"A phase 1/2 trial of SI-B001 in head and neck squamous cell carcinoma, run by Sichuan Baili Pharmaceutical Co., Ltd., active and no longer recruiting.","summary":"A Study of SI-B001+SI-B003± Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma is a phase 1/2 interventional study registered as NCT05668858 by Sichuan Baili Pharmaceutical Co., Ltd., with 70 participants enrolled, started 2023-02-10 and due to reach its primary completion in 2026-12. Interventions recorded: SI-B001 and SI-B003.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05668858","url":"https://clinicaltrials.gov/study/NCT05668858"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["si-b001"],"companies":["systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05668858","phase":"1/2","setting":"A Phase Ib/II Clinical Study of SI-B001+SI-B003 Dual-drug No-combination or Combined Chemotherapy in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct05668858/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"}],"drug":[{"id":"si-b001","kind":"drug","name":"SI-B001","route":"/drugs/si-b001/"}],"company":[{"id":"systimmune","kind":"company","name":"SystImmune / Sichuan Biokin","route":"/companies/systimmune/"}]}}